Microalbuminuria

Revision as of 12:58, 7 December 2010 by C Michael Gibson (talk | contribs)
Jump to navigation Jump to search

Template:SignSymptom infobox

WikiDoc Resources for Microalbuminuria

Articles

Most recent articles on Microalbuminuria

Most cited articles on Microalbuminuria

Review articles on Microalbuminuria

Articles on Microalbuminuria in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Microalbuminuria

Images of Microalbuminuria

Photos of Microalbuminuria

Podcasts & MP3s on Microalbuminuria

Videos on Microalbuminuria

Evidence Based Medicine

Cochrane Collaboration on Microalbuminuria

Bandolier on Microalbuminuria

TRIP on Microalbuminuria

Clinical Trials

Ongoing Trials on Microalbuminuria at Clinical Trials.gov

Trial results on Microalbuminuria

Clinical Trials on Microalbuminuria at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Microalbuminuria

NICE Guidance on Microalbuminuria

NHS PRODIGY Guidance

FDA on Microalbuminuria

CDC on Microalbuminuria

Books

Books on Microalbuminuria

News

Microalbuminuria in the news

Be alerted to news on Microalbuminuria

News trends on Microalbuminuria

Commentary

Blogs on Microalbuminuria

Definitions

Definitions of Microalbuminuria

Patient Resources / Community

Patient resources on Microalbuminuria

Discussion groups on Microalbuminuria

Patient Handouts on Microalbuminuria

Directions to Hospitals Treating Microalbuminuria

Risk calculators and risk factors for Microalbuminuria

Healthcare Provider Resources

Symptoms of Microalbuminuria

Causes & Risk Factors for Microalbuminuria

Diagnostic studies for Microalbuminuria

Treatment of Microalbuminuria

Continuing Medical Education (CME)

CME Programs on Microalbuminuria

International

Microalbuminuria en Espanol

Microalbuminuria en Francais

Business

Microalbuminuria in the Marketplace

Patents on Microalbuminuria

Experimental / Informatics

List of terms related to Microalbuminuria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Microalbuminuria occurs when the kidney leaks small amounts of albumin into the urine, in other words, when there is an abnormally high permeability[disambiguation needed] for albumin in the renal glomerulus.

Diagnosis

The level of albumin protein produced by microalbuminuria cannot be detected by urine dipstick methods. A microalbumin urine test determines the presence of the albumin in urine. In a properly functioning body, albumin is not normally present in urine because it is retained in the bloodstream by the kidneys.

Microalbuminuria is diagnosed either from a 24-hour urine collection (between 30-300 mg/24 hours) or, more commonly, from elevated concentrations in a spot sample (30 to 300 mg/L). Both must be measured on at least two of three measurements over a two- to three-month period.[1]. An albumin level above these values is called "macroalbuminuria", or sometimes just albuminuria.

To compensate for variations in urine concentration in spot-check samples, it is more typical in the United Kingdom to compare the amount of albumin in the sample against its concentration of creatinine. This is termed the albumin/creatinine ratio (ACR)[2] and microalbuminuria is defined as ACR ≥3.5 mg/mmol (female) or ≥2.5 mg/mmol(male),[3] or, with both substances measured by mass, as an ACR between 30 and 300 µg albumin/mg creatinine[4].

Significance

See also

References

  • Abid O, Sun Q, Sugimoto K, Mercan D, Vincent JL (2001). "Predictive value of microalbuminuria in medical ICU patients: results of a pilot study". Chest. 120 (6): 1984–8. doi:10.1378/chest.120.6.1984. PMID 11742932.
  • Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD (2000). "Glomerular permselectivity in early stages of overt diabetic nephropathy". Kidney Int. 58 (5): 2129–37. doi:10.1111/j.1523-1755.2000.00386.x. PMID 11044234.
  • Heart Outcomes Prevention Evaluation Study Investigators (2000). "Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy". Lancet. 355 (9200): 253–9. doi:10.1016/S0140-6736(99)12323-7. PMID 10675071.
  • Lemley KV, Abdullah I, Myers BD; et al. (2000). "Evolution of incipient nephropathy in type 2 diabetes mellitus". Kidney Int. 58 (3): 1228–37. doi:10.1046/j.1523-1755.2000.00223.x. PMID 10972685.
  • Lièvre M, Marre M, Chatellier G; et al. (2000). "The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group". Controlled clinical trials. 21 (4): 383–96. doi:10.1016/S0197-2456(00)00060-X. PMID 10913814.
  • Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P (2001). "The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes". N. Engl. J. Med. 345 (12): 870–8. doi:10.1056/NEJMoa011489. PMID 11565519.

Footnotes

  1. "Person—microalbumin level (measured), total micrograms per minute N[NNN].N". Retrieved 2007-07-05.
  2. PMID 10333950
  3. "Proteinuria". UK Renal Association. December 15, 2005.
  4. clinlabnavigator.com > Test Interpretations Last Updated on Saturday, 19 June 2010
  5. http://www.ncbi.nlm.nih.gov/pubmed/19417196

External links